Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy (MACAARET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02444832|
Recruitment Status : Unknown
Verified May 2015 by Federico Zarco, Hospital Clinic of Barcelona.
Recruitment status was: Recruiting
First Posted : May 15, 2015
Last Update Posted : May 15, 2015
Based on the anatomical features of the anterior Communicating artery complex, the investigators will analyze the outcome of the ACoA aneurysms treated by endovascular therapy.
The most common site of intracranial aneurysms is the anterior communicating artery (AcomA). AcomA aneurysms account for approximately one-fourth of all intracranial aneurysms.
Recent publications have addressed specifically the endovascular treatment of AcoA aneurysms. Furthermore, detailed anatomic characteristics and the effects of the multiple variations of the anterior communicating artery complex have scarcely been reported.
The hemodynamic factors play a fundamental role in the adequate treatment of aneurismal coiling.
The objective of our registry is to analyze the impact of morphological configuration of the anterior communicating artery complex and the results of coil embolization in AcoA aneurysms
|Condition or disease|
|Intracranial Aneurysm Anterior Communicating Artery Aneurysm Cerebral Aneurysm Aneurysm, Ruptured|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||December 2017|
- Effective Aneurysm Coiling (no residual cerebral aneurysm) [ Time Frame: 1 year ]
- All Cause Mortality [ Time Frame: 1 year ]
- Neurological Outcome (classified with the Glasgow Outcome Scale, Rankin Scale) [ Time Frame: 1 year ]All patients will be classified with the Glasgow Outcome Scale, Rankin Scale.
- Procedural device-related serious adverse events [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02444832
|Contact: Federico Zarco, MD||932275400 ext email@example.com|
|Barcelona, Spain, 08036|
|Contact: Federico Zarco, MD 932 27 54 00 ext 2662 firstname.lastname@example.org|
|Principal Investigator: Federico Zarco, MD|
|Principal Investigator: Antonio Lopez Rueda, MD|
|Sub-Investigator: Juan Macho Fernandez, MD|
|Sub-Investigator: Fernando Delgado, MD|
|Sub-Investigator: Alejandro González García, MD|
|Sub-Investigator: Mariano Werner, MD|
|Sub-Investigator: Oscar Chirife, MD|
|Sub-Investigator: Napoleón Macias, MD|
|Sub-Investigator: Luis San Roman, MD|
|Sub-Investigator: Jordi Blasco, MD|
|Principal Investigator:||Federico Zarco, MD||Hospital Clinic of Barcelona|